Various components of the insulin‐like growth factor system in tumor tissue, cerebrospinal fluid and peripheral blood of pediatric medulloblastoma and ependymoma patients

The insulin‐like growth factor (IGF) system plays an important role in neuronal development and may contribute to the development of brain tumors. In this study, we studied mRNA expression levels of IGFs, insulin‐like growth factor binding proteins (IGFBPs) and insulin‐like growth factor receptors (IGFRs) in 27 pediatric medulloblastomas, 13 pediatric ependymomas and 5 control cerebella. Compared to normal cerebellum, mRNA levels of IGFBP‐2 and IGFBP‐3 were significantly increased in medulloblastomas and ependymomas. IGFBP‐2 expression was indicative of poor prognosis in medulloblastomas, whereas IGFBP‐3 mRNA levels were especially high in anaplastic ependymomas. IGFBP‐5 and IGF‐II mRNA levels were significantly increased in ependymomas compared to control cerebellum. Protein expression levels of IGFs and IGFBPs were analyzed in the cerebrospinal fluid (CSF) of 16 medulloblastoma, 4 ependymoma and 23 control patients by radioimmuno assay to determine whether they could be used as markers for residual disease after surgery. No aberrant CSF protein expression levels were found for ependymoma patients. In medulloblastoma patients, the IGFBP‐3 protein levels were significantly higher than in ependymoma patients and controls. Moreover, enhanced levels of proteolytic fragments of IGFBP‐3 were found in the CSF of medulloblastoma patients, being in concordance with a significantly increased IGFBP‐3 proteolytic activity in the CSF of these patients. In conclusion, our data suggest that the IGF system is of importance in pediatric medulloblastomas and ependymomas. Larger studies should be conducted to validate the predictive values of the levels of intact IGFBP‐3 and proteolytic fragments in CSF in the follow‐up of medulloblastomas. © 2008 Wiley‐Liss, Inc.

[1]  M. D. Den Boer,et al.  Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis. , 2008, Neuro-oncology.

[2]  S. Zacharoulis,et al.  Pediatric CNS tumors: current treatment and future directions , 2007, Expert review of neurotherapeutics.

[3]  S. Nakano,et al.  Silencing of Insulin-like Growth Factor-binding Protein-2 in Human Glioblastoma Cells Reduces Both Invasiveness and Expression of Progression-associated Gene CD24* , 2007, Journal of Biological Chemistry.

[4]  D. Leroith,et al.  The role of the IGF system in cancer growth and metastasis: overview and recent insights. , 2007, Endocrine reviews.

[5]  O. Fodstad,et al.  Association of insulin-like growth factor binding protein-3 expression with melanoma progression , 2006, Molecular Cancer Therapeutics.

[6]  Sarah K. Johnson,et al.  Differential expression of insulin‐like growth factor binding protein‐5 in pancreatic adenocarcinomas: Identification using DNA microarray , 2006 .

[7]  J. Holly,et al.  The Role of Insulin-Like Growth Factor Binding Proteins , 2006, Neuroendocrinology.

[8]  G. Fuller,et al.  Overexpression of IGFBP5, but not IGFBP3, Correlates with the Histologic Grade of Human Diffuse Glioma: A Tissue Microarray and Immunohistochemical Study , 2006, Technology in cancer research & treatment.

[9]  E. Hébert.  Mannose-6-phosphate/Insulin-like Growth Factor II Receptor Expression and Tumor Development , 2006, Bioscience reports.

[10]  J. Beattie,et al.  Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. , 2006, The Biochemical journal.

[11]  P. Gluckman,et al.  The insulin-like growth factor system and its pleiotropic functions in brain. , 2005, Endocrine reviews.

[12]  H. Yi,et al.  Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells. , 2005, Biochemical and biophysical research communications.

[13]  U. Schüller,et al.  Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cells. , 2005, The American journal of pathology.

[14]  P. Wesseling,et al.  Differential patterns of insulin‐like growth factor‐I and ‐II mRNA expression in medulloblastoma , 2004, Neuropathology and applied neurobiology.

[15]  G. Rao,et al.  Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice , 2004, Oncogene.

[16]  S. Vanhatalo,et al.  Cerebrospinal fluid insulin‐like growth factor‐1, insulin growth factor binding protein‐2 or nitric oxide are not increased in MS or ALS , 2004, Acta neurologica Scandinavica.

[17]  R. Gilbertson,et al.  Medulloblastoma: signalling a change in treatment. , 2004, The Lancet. Oncology.

[18]  J. Ricort,et al.  Insulin-like growth factor binding protein-3 stimulates phosphatidylinositol 3-kinase in MCF-7 breast carcinoma cells. , 2004, Biochemical and biophysical research communications.

[19]  P. Lichter,et al.  Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. , 2003, The American journal of pathology.

[20]  Robert L Strausberg,et al.  Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes , 2003, Oncogene.

[21]  G. Fuller,et al.  Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. , 2003, Cancer research.

[22]  S. Armstrong,et al.  Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. , 2003, Blood.

[23]  Li Mao,et al.  Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  J. van Doorn,et al.  Antibodies directed against the E region of pro-insulin-like growth factor-II used to evaluate non-islet cell tumor-induced hypoglycemia. , 2002, Clinical chemistry.

[25]  W. Zumkeller.  IGFs and IGF-binding proteins as diagnostic markers and biological modulators in brain tumors , 2002, Expert review of molecular diagnostics.

[26]  Martin Vingron,et al.  Variance stabilization applied to microarray data calibration and to the quantification of differential expression , 2002, ISMB.

[27]  S. Croul,et al.  Insulin-like growth factor I receptor activity in human medulloblastomas. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  T. Mathiesen,et al.  Expression of IGF-II, IGFBP-2, -5, and -6 in Meningiomas with Different Brain Invasiveness , 2002, Journal of Neuro-Oncology.

[29]  G. Reifenberger,et al.  The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.

[30]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[31]  M. Westphal,et al.  The IGF/IGFBP system in CNS malignancy , 2001, Molecular pathology : MP.

[32]  S. Croul,et al.  Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas , 2001, Oncogene.

[33]  R. Baxter.  Signalling pathways involved in antiproliferative effects of IGFBP-3: a review , 2001, Molecular pathology : MP.

[34]  J. van Doorn,et al.  Plasma levels of insulin‐like growth factor binding protein‐4 (IGFBP‐4) under normal and pathological conditions , 2001, Clinical endocrinology.

[35]  S. Ogino,et al.  Comparative Immunohistochemical Study of Insulin-like Growth Factor II and Insulin-like Growth Factor ReceptorType 1 in Pediatric Brain Tumors , 2001, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[36]  Andreas Zimmer,et al.  Patched Target Igf2 Is Indispensable for the Formation of Medulloblastoma and Rhabdomyosarcoma* , 2000, The Journal of Biological Chemistry.

[37]  M. Gleave,et al.  Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. , 2000, Cancer research.

[38]  J. W. Neck,et al.  Human insulin-like growth factor (IGF) binding protein-1 inhibits IGF-I-stimulated body growth but stimulates growth of the kidney in snell dwarf mice. , 2000, Endocrinology.

[39]  Kuijpers,et al.  Circulating levels of human insulin‐like growth factor binding protein‐6 (IGFBP‐6) in health and disease as determined by radioimmunoassay , 1999, Clinical endocrinology.

[40]  R. Rosenfeld,et al.  Insulin-like growth factor binding proteins (IGFBPs) and IGFBP-related protein 1-levels in cerebrospinal fluid of children with acute lymphoblastic leukemia. , 1999, The Journal of clinical endocrinology and metabolism.

[41]  N. Wilczak,et al.  Insulin-like growth factor system in serum and cerebrospinal fluid in patients with multiple sclerosis , 1998, Neuroscience Letters.

[42]  J. Wit,et al.  Plasma Levels of Insulin-Like Growth Factor (IGF)-I, IGF-II and IGF-Binding Protein-3 in the Evaluation of Childhood Growth Hormone Deficiency , 1998, Hormone Research in Paediatrics.

[43]  C. Hoogerbrugge,et al.  Insulin-like growth factor-binding protein-3 protease activity in Snell normal and Pit-1 deficient dwarf mice. , 1998, The Journal of endocrinology.

[44]  M. Binoux,et al.  Prostate carcinoma (PC-3) cell proliferation is stimulated by the 22-25-kDa proteolytic fragment (1-160) and inhibited by the 16-kDa fragment (1-95) of recombinant human insulin-like growth factor binding protein-3. , 1998, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[45]  M. Binoux,et al.  A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. , 1996, Endocrinology.

[46]  S. Velasco-Miguel,et al.  Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.

[47]  R. Packer.  Brain tumors in children. , 1995, Current opinion in pediatrics.

[48]  I. Pollack.  Brain tumors in children. , 1994, The New England journal of medicine.

[49]  W. Blum,et al.  Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. , 1994, The Journal of clinical endocrinology and metabolism.

[50]  R. Hintz,et al.  Concentrations of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), IGF, and IGFBP-3 protease activity in cerebrospinal fluid of children with leukemia, central nervous system tumor, or meningitis. , 1993, The Journal of clinical endocrinology and metabolism.

[51]  H. Werner,et al.  Cellular pattern of type-I insulin-like growth factor receptor gene expression during maturation of the rat brain: Comparison with insulin-like growth factors I and II , 1992, Neuroscience.

[52]  T. Unterman,et al.  Production of insulin-like growth factor-binding proteins by human central nervous system tumors. , 1991, Cancer research.

[53]  J. Wit,et al.  Plasma Insulin-Like Growth Factors (IGFs), IGF-Binding Proteins (IGFBPs), Acid-Labile Subunit (ALS) and IGFBP-3 Proteolysis in Individuals with Clinical Characteristics of Sotos Syndrome , 2004, Journal of pediatric endocrinology & metabolism : JPEM.

[54]  M. Elmlinger,et al.  In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. , 2001, Endocrinology.

[55]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .